#Canada #Duchesnay #Blainville #pharmaceuticals #Advisory Board

Duchesnay Pharmaceutical Group Establishes New Advisory Board

In a bid to foster its growth and expand its global reach, Duchesnay Pharmaceutical Group (DPG) recently announced the formation of a new Advisory Board, comprising five distinguished members from various industries. This initiative comes on the heels of DPG being recognized with the 2024 Life Sciences Innovation Award from ADRIQ. The new board aims to provide essential guidance and strategic insight that aligns with DPG's mission of advancing pharmaceutical innovations while ensuring solid governance.

A Step Towards Strategic Direction

The Advisory Board, which convened for the first time recently, will play a vital role in monitoring DPG's activities and performance. Unlike a conventional board of directors, the Advisory Board does not hold legal authority but is designed to offer expert advice and counsel based on the members' extensive experience in their respective fields.

DPG President Éric Gervais highlighted the importance of the Advisory Board, stating, "The creation of our new Advisory Board is a pivotal step in DPG's development. It signifies our dedication to collaboration and excellence, allowing us to be at the forefront of pharmaceutical innovation through informed and strategic decision-making."

Diverse Expertise in the Boardroom

The five initial members appointed to the Advisory Board bring a wealth of knowledge and expertise, ensuring that DPG is well-equipped to navigate the complexities of the pharmaceutical industry:

1. François Lecavalier - Serving as the first Chairman, Lecavalier is a seasoned business leader and consultant specializing in clean technology and infrastructure. He has held influential positions with the Canadian Department of Finance and the European Bank for Reconstruction and Development.

2. Ela Borenstein - Vice President of Venture Capital at the Business Development Bank of Canada, Borenstein is well-versed in financial programs aimed at bolstering the Canadian venture capital landscape. She also teaches a course for future healthcare entrepreneurs at McGill University.

3. Bertrand Bolduc - This prominent figure in the pharmaceutical sector is the President and CEO of PharmaLube Technologies and has served as the President of the Ordre des Pharmaciens du Québec for nine years. He is also an active member of various boards in healthcare.

4. Dr. Céline Desjardins - An obstetrician and gynecologist, Dr. Desjardins is involved in several committees focusing on sexual and reproductive health. Her extensive background includes managerial roles at Health Canada.

5. Michelle Keefe - As a healthcare executive, Keefe has had a distinguished career in major pharmaceutical firms, including Pfizer and Syneos Health, bringing valuable insights from her experiences in both corporate and advisory capacities.

A Commitment to Future Success

The Advisory Board is expected to convene at least four times per year, ensuring continuous engagement and support as DPG moves forward with its strategic plans. Lecavalier reiterated the board's mission, emphasizing the importance of maintaining solid governance and facilitating continued growth in an increasingly competitive environment.

Duchesnay Pharmaceutical Group, headquartered in Blainville, Quebec, comprises six companies dedicated to meeting patient needs in Canada and internationally. With specialties ranging from women's health to treatments for rare diseases, DPG is poised to make significant advances in the pharmaceutical landscape.

The establishment of the Advisory Board marks DPG's commitment to fostering innovation while nurturing a positive organizational culture, characterized by collaboration and flexibility. As the group embraces new challenges and opportunities, this board will be integral to shaping the future trajectory of DPG in the global pharmaceutical market.

For more information about Duchesnay Pharmaceutical Group, visit duchesnaypharmaceuticalgroup.com.